Loading...
XPAR
GNFT
Market cap207mUSD
Jun 16, Last price  
3.63EUR
1D
-0.55%
1Q
7.72%
Jan 2017
-82.72%
IPO
-71.13%
Name

Genfit SA

Chart & Performance

D1W1MN
P/E
—
P/S
6.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.78%
Rev. gr., 5y
233.73%
Revenues
29m
+41.45%
12,774,60010,051,9009,477,3008,760,6005,812,2003,757,5002,360,9001,672,3001,899,3001,614,400527,000284,000118,00069,00030,839,000765,00080,069,00020,195,00028,565,000
Net income
-29m
L+21.81%
1,773,100327,700-2,800,800-3,960,500-7,373,900-9,380,600-9,681,700-5,411,600-12,652,100-17,025,500-17,135,000-33,667,000-58,604,000-79,521,000-65,145,000-101,221,00067,259,000-23,720,000-28,894,000
CFO
-55m
L-23.69%
1,675,500-1,743,400-4,814,000-5,162,800-221,000-5,393,800-7,113,700-7,861,900-9,191,200-15,491,400-14,870,000-27,226,000-49,856,000-56,081,000-47,680,000-96,371,00099,915,000-72,638,000-55,429,000
Earnings
Sep 17, 2025

Profile

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
URL
https://www.genfit.fr/
IPO date
Dec 19, 2006
Employees
148
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
28,565
41.45%
20,195
-74.78%
Cost of revenue
55,092
53,463
Unusual Expense (Income)
NOPBT
(26,527)
(33,268)
NOPBT Margin
Operating Taxes
380
(116)
Tax Rate
NOPAT
(26,907)
(33,152)
Net income
(28,894)
21.81%
(23,720)
-135.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
5
BB yield
0.00%
Debt
Debt current
7,926
5,080
Long-term debt
68,137
76,754
Deferred revenue
9,706
Other long-term liabilities
5,188
1,231
Net debt
(4,545)
(63,631)
Cash flow
Cash from operating activities
(55,429)
(72,638)
CAPEX
(414)
Cash from investing activities
2,234
(46,266)
Cash from financing activities
(5,098)
(3,786)
FCF
(31,364)
(32,347)
Balance
Cash
77,789
140,551
Long term investments
2,819
4,914
Excess cash
79,180
144,455
Stockholders' equity
(376,339)
(350,154)
Invested Capital
519,657
525,988
ROIC
ROCE
EV
Common stock shares outstanding
49,700
49,674
Price
3.54
-10.79%
3.97
-8.06%
Market cap
175,939
-10.74%
197,106
-17.88%
EV
171,394
133,475
EBITDA
(24,873)
(31,436)
EV/EBITDA
Interest
4,624
4,758
Interest/NOPBT